🔎 Trials Near Me

Hem › Sklerodermi › New York

Kliniska studier för Sklerodermi i New York

11 studier för Sklerodermi söker deltagare vid platser i New York.

Städer i New York

Officiell studietext (engelska)

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  • Hospital for Special Surgery, New York
  • Icahn School of Medicine at Mount Sinai, New York
  • Columbia University Medical Center-New York Presbyterian Hospital, New York
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 30 sep. 2026 · NCT07497087

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • NYU Langone Hospital - Long Island, Mineola
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
  • och 1 fler
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 23 sep. 2026 · NCT03816345

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

  • Icahn School of Medicine at Mount Sinai, New York
RekryterarFas 1
Ålder 18 till 74 · Alla kön · Uppdaterad 10 sep. 2026 · NCT07085104

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

  • GSK Investigational Site, New York
  • GSK Investigational Site, New York
RekryterarFas 2/3
Ålder 18 och äldre · Alla kön · Uppdaterad 8 sep. 2026 · NCT05878717

Platform Clinical Study for Conquering Scleroderma

  • Northwell Health, Great Neck
  • Hospital for Special Surgery, New York
  • Columbia University Medical Center, New York
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 18 aug. 2026 · NCT06195072

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

  • Columbia University Irving Medical Center, New York
  • University of Rochester, Rochester
RekryterarFas 2/3
Ålder 18 till 75 · Alla kön · Uppdaterad 17 aug. 2026 · NCT06328777

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

  • Nkarta Investigational Site, New York
  • Nkarta Investigational Site, Stony Brook
  • Nkarta Investigational Site, Syracuse
RekryterarFas 1/2
Ålder 18 till 75 · Alla kön · Uppdaterad 7 aug. 2026 · NCT06733935

A Study of AZD0120 in Autoimmune Diseases

  • Research Site, New York
RekryterarFas 1
Ålder 18 till 75 · Alla kön · Uppdaterad 28 juli 2026 · NCT07295847

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

  • Montefiore Medical Center, New York
RekryterarFas 1
Ålder 12 till 70 · Alla kön · Uppdaterad 22 maj 2026 · NCT06308978

Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

  • Hospital for Special Surgery, New York
RekryterarFas 2
Ålder 18 till 80 · Alla kön · Uppdaterad 27 mars 2026 · NCT03844061

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

  • aTyr Investigative Site, New York
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 7 maj 2025 · NCT05892614

Från ClinicalTrials.gov, data hämtad 2 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.